Document is current
Any future updates will be listed below
-
Authors
Oehler, Vivian G. https://orcid.org/0000-0002-1630-4151
Sala-Torra, Olga https://orcid.org/0000-0002-8067-2581
Gilderman, Neta https://orcid.org/0009-0007-1954-9414
Beppu, Lan
Woolston, David W. https://orcid.org/0009-0004-0006-5311
Namaganda, Priscilla
Rynning, Jennifer
González, Inés García
Towlerton, Andrea
Voutsinas, Jenna
Wu, Qian https://orcid.org/0000-0002-2292-4816
Yeung, Cecilia C. S. https://orcid.org/0000-0001-6799-2022
Radich, Jerald P.
- License Information
-
More Information
Article History
Received: 26 August 2025
Revised: 18 November 2025
Accepted: 12 December 2025
First Online: 23 January 2026
Competing interests
: Dr. Oehler has received research funding from Novartis, Ascentage Pharma, Terns Pharma, and Pfizer, and honoraria from Takeda. Dr. Yeung has received research funding in the form of reagent donations from Archer. Dr. Radich has received advisory honoraria from Thermo Fisher and Novartis. Jennifer Rynning and Ines Garcia-Gonzalez represent The Max Foundation, which receives in-kind donations of medicines and diagnostics for programs, as well as financial support from Novartis, Takeda, Bristol Myers Squibb, BeOne, Pfizer, Eli Lilly, Incyte, Cepheid and BD.
